India  
 
NewsR.in

Sarepta shares fall 37% as FDA questions future of key gene therapy

Invezz Friday, 18 July 2025 ()
Sarepta shares fall 37% as FDA questions future of key gene therapyShares of Sarepta Therapeutics fell close to 37% on Friday after reports emerged that the US Food and Drug Administration is considering whether to halt the distribution of Elevidys, the company’s flagship gene therapy for Duchenne Muscular Dystrophy (DMD). The move comes amid an ongoing investigation into multiple patient deaths tied to Sarepta’s gene therapy […]
0
shares		ShareTweetSavePostSend
 

You Might Like


Related videos from verified sources

FDA Roundtable on Cell and Gene Therapy [Video]

FDA Roundtable on Cell and Gene Therapy

WASHINGTON, DC—June 4, 2025—Media and the public are invited to listen to the FDA’s Center for Biologics Evaluation and Research (CBER) Cell and Gene Therapy (CGT) Roundtable. This event will..

Credit: RumblePublished
An Amazing Therapy Surgery Allows This 11-Year-Old To Hear For the First Time [Video]

An Amazing Therapy Surgery Allows This 11-Year-Old To Hear For the First Time

A child with hereditary deafness regained their hearing thanks to a successful gene therapy surgery. 11-year-old Aissam Dam became the first person to get gene therapy in the United States for..

Credit: Veuer     Duration: 01:01Published